FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) granted approval to atezolizumab and durvalumab in March of 2019 and 2020, respectively, for use in combination with chemotherapy for first‐line treatment of patients with extensive stage small cell lung cancer. These approvals were based on data from two...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Mathieu, Luckson, Shah, Sujay, Pai‐Scherf, Lee, Larkins, Erin, Vallejo, Jonathon, Li, Xiaoxue, Rodriguez, Lisa, Mishra‐Kalyani, Pallavi, Goldberg, Kirsten B., Kluetz, Paul G., Theoret, Marc R., Beaver, Julia A., Pazdur, Richard, Singh, Harpreet
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100557/
https://ncbi.nlm.nih.gov/pubmed/33687763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13752
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados